Clinical Trials Sponsored by AstraZeneca Pharmaceuticals" LLC

Total 765 results

Infinity Pharmaceuticals, Inc.
AstraZeneca; MedImmune LLC

Terminated

Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

Gastrointestinal Stromal Tumors
SCRI Development Innovations, LLC
AstraZeneca; Aventis Pharmaceuticals

Completed

Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer

Head and Neck Cancer

United States
SCRI Development Innovations, LLC
GlaxoSmithKline; AstraZeneca; Aventis Pharmaceuticals

Completed

Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer

Lung Cancer

United States
AstraZeneca
MedImmune LLC

Completed

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany, United States, Canada, Russian Federation, Slovakia, Czechia, Bulgaria, Mexico
AstraZeneca
MedImmune LLC

Completed

Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus

Type 2 Diabetes

Japan
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season (FluMist)

Healthy | Influenza

United States
AstraZeneca
MedImmune LLC

Completed

Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects

Cancer | Advanced Solid Malignancies

Japan
MedImmune LLC
AstraZeneca

Terminated

A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Mexico, Peru, South Africa, Canada
MedImmune LLC
AstraZeneca

Completed

An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHF (CD-1089)

Respiratory Syncytial Virus, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure

United States, Bulgaria, France, Russian Federation, Canada, Sweden, Germany, Italy, Czech Republic
AstraZeneca
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects

Healthy

Japan
MedImmune LLC
AstraZeneca

Completed

A Study to Evaluate BioMarkers in Blood Samples in Subjects With Rheumatoid Arthritis

Arthritis

United States
AstraZeneca
MedImmune LLC

Terminated

Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee

Pain | Osteoarthritis

United Kingdom
AstraZeneca
MedImmune LLC

Active, not recruiting

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

Spain, United States, Belgium, Germany, United Kingdom, Italy
MedImmune LLC
AstraZeneca

Suspended

A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age (ICICLE)

Influenza Vaccine Effectiveness

United States, United Kingdom
MedImmune LLC
AstraZeneca

Completed

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Carcinoma, Non-Small-Cell Lung

United States, Korea, Republic of, Japan
AstraZeneca
MedImmune LLC

Completed

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (TERRANOVA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Denmark, France, Sweden, Thailand, Vietnam, Belgium, Brazil, Peru, Philippines, Turkey, Taiwan, Argentina, Australia, Israel, Poland, Ukraine, Slovenia, Serbia, Mexico, Bulgaria, Colombia, New Zealand, Chile, Norway, Croatia
AstraZeneca
MedImmune LLC

Completed

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (GALATHEA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
AstraZeneca
MedImmune LLC

Completed

Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus

Japan
AstraZeneca
MedImmune LLC

Completed

A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus

Japan
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season (FluMist)

Healthy | Influenza

United States
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season (FluMist)

Healthy | Influenza

United States
MedImmune LLC
AstraZeneca

Completed

A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Poland, Spain, United Kingdom, Denmark, Canada, Germany
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Healthy | Influenza

United States
AstraZeneca
MedImmune LLC

Completed

A Study of MEDI-575 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
PrECOG, LLC.
AstraZeneca

Completed

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505)

Mesothelioma | Pleural Mesothelioma

United States
MedImmune LLC
AstraZeneca

Completed

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age (FluMist)

Healthy | Influenza

United States
PrECOG, LLC.
AstraZeneca

Completed

Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer

United States
AstraZeneca
MedImmune LLC

Completed

A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies

Blood Cancer | Advanced B Cell Malignancies

Japan
AstraZeneca
MedImmune LLC

Completed

D2212C00002 J-Phase II Study

Idiopathic Pulmonary Fibrosis

Japan
MedImmune LLC
AstraZeneca

Completed

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Influenza

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS (OS440-3004)

Multiple Sclerosis | Spasticity, Muscle

Serbia, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Moldova, Republic of, Poland
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
Amneal Pharmaceuticals, LLC
Novum Pharmaceutical Research Services

Completed

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS (OS440-3005)

Multiple Sclerosis | Spasticity, Muscle

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
AstraZeneca
Acerta Pharma, LLC

Completed

A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers

Pharmacokinetics | Bioavailability

United States
AstraZeneca
Acerta Pharma, LLC

Completed

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

Bioavailability | B-cell Lymphoid Cancer

United States
AstraZeneca
Parexel; MedImmune LLC

Recruiting

Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

Asthma

United States, Puerto Rico
Impax Laboratories, LLC
AstraZeneca

Completed

Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE

Migraine

United States
Fusion Pharmaceuticals Inc.
AstraZeneca

Recruiting

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Advanced Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Metastatic Colorectal Carcinoma

United States, Canada
Alexion Pharmaceuticals, Inc.
AstraZeneca

Recruiting

Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China (Soliris)

Atypical Hemolytic Uremic

China
Ionis Pharmaceuticals, Inc.
AstraZeneca

Recruiting

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Portugal, Spain, Sweden, United Kingdom, Australia, Greece
Ionis Pharmaceuticals, Inc.
AstraZeneca

Active, not recruiting

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

United States, United Kingdom, Italy, Spain
AVEO Pharmaceuticals, Inc.
AstraZeneca

Terminated

A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma (DEDUCTIVE)

Hepatocellular Carcinoma

United States
AstraZeneca
KuDOS Pharmaceuticals Limited

Completed

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer (ICEBERG 2)

Ovarian Neoplasm

United States, Spain, Australia, Germany, Sweden
Ionis Pharmaceuticals, Inc.
AstraZeneca

Completed

Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers

Lymphoma | DLBCL | Advanced Cancers

United States
AstraZeneca
Fougera Pharmaceuticals Inc.

Withdrawn

A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)

Dermatitis
AstraZeneca
KuDOS Pharmaceuticals Limited

Completed

Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

Neoplasm Metastasis

United Kingdom
Ionis Pharmaceuticals, Inc.
AstraZeneca

Active, not recruiting

The CARDIO-TTRansform Scintigraphy Sub-study

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

United States, Spain

Clinical Trials Sponsored by AstraZeneca Pharmaceuticals" LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations